ORIGINAL ARTICLE Giugliano, RP et al. Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial. Lancet http://dx. doi. org/10.1016/S0140-6736 (17) 32290-0 (2017) FURTHER READING Shapiro, MD et al. Dyslipidaemia: the PCSK9 adventure—humanizing extreme LDL lowering. Nat. Rev. Cardiol. 14, 319–320 (2017) a steady decline in risk of the primary efficacy outcome was observed with the reduction in LDL-cholesterol level